Aktis Oncology Enters Into Strategic Collaboration With Lilly to ...

BOSTON, May 21, 2024 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, …

CouponFollow Extension

$1
OFF

Eli Lilly And Aktis Enter $1bn Partnership To Develop Anticancer ...

4 weeks from now

May 23, 2024 · Eli Lilly has entered into a strategic multi-target discovery collaboration agreement with Aktis Oncology in a deal worth more than $1bn to develop novel anticancer …

pmlive.com

$1
OFF

Lilly Inks Potential $1.1B Radiopharma Deal With Aktis Oncology

4 weeks from now

May 21, 2024 · Eli Lilly is paying $60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals, as radiopharma dealmaking continues to heat up …

biospace.com

$1
OFF

Aktis To Collaborate With Eli Lilly On Cancer Therapies - ETPharma.com

4 weeks from now

May 22, 2024 · London: Aktis Oncology said on Tuesday it will collaborate with Eli Lilly to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties …

indiatimes.com

$60
OFF

Lilly Pays Aktis $60M To Further Dial Into Radiopharma Signal

4 weeks from now

May 21, 2024 · Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets. Lilly …

fiercebiotech.com

$1
OFF

Aktis To Collaborate With Eli Lilly On Cancer Therapies

4 weeks from now

May 21, 2024 · Aktis Oncology said on Tuesday it will collaborate with Eli Lilly LLY to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties …

tradingview.com

FAQs about Aktis Oncology Enters Into Strategic Collaboration With Lilly to ... Coupon?

Is Eli Lilly partnering with aktis oncology?

Eli Lilly is partnering with biotechnology company Aktis Oncology to develop radiopharmaceuticals for cancer, agreeing to a deal that will pay the startup $60 million upfront. Per terms announced Tuesday, Aktis could receive as much as $1.1 billion more from Lilly if certain milestones are met. Lilly is also making an equity investment in Aktis. ...

How much money will aktis receive from Lilly?

Under the terms of the agreement, Aktis will receive a $60 million upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly. In addition, Aktis will be eligible to receive up to an additional $1.1 billion in potential preclinical, clinical, regulatory and commercial milestones, as well as tiered royalties. ...

Who is aktis oncology?

Related article: Eli Lilly Expands Oncology Portfolio with $1.4 Billion Acquisition of POINT Biopharma Aktis Oncology is at the forefront of developing targeted alpha radiopharmaceuticals designed to treat a wide range of solid tumors. ...

What is aktis partnering with Lilly?

The partnership, which may be worth up to $1.16 billion, aims to harness Aktis’ innovative miniprotein technology platform in conjunction with Lilly’s extensive oncology expertise and commercialization prowess. Together, they seek to develop first-in-class and differentiated radiopharmaceutical therapeutics targeting a variety of solid tumors. ...

Will Lilly get the rights to develop aktis treatments?

Lilly will get the rights to develop treatments discovered by Aktis. “We are pleased to partner with Lilly in efforts to increase the number of patients that can derive meaningful clinical benefit from targeted radiopharmaceuticals,” Matthew Roden, President and Chief Executive Officer of Aktis Oncology, said in a statement. ...

Will Lilly acquire aktis pharmaceuticals?

Under the terms of the agreement, Lilly will gain worldwide rights to develop targets for radiopharmaceuticals discovered by Aktis. However, the deal does not include Aktis’ current pipeline, which consists of seven programmes. ...